Neurodegenerative disease Archives

probiodrug alzheimers disease mechanism of action

News and Trends 30 Aug 2017

German Scientists Publish New Mechanism of Action Against Alzheimer’s

Researchers at the German biotech Probiodrug have published today the detailed mechanism of action of a drug that might succeed in treating Alzheimer’s where many others have failed. Probiodrug is developing a therapeutic antibody with a unique mode of action against Alzheimer’s, PBD-C06. The company announced yesterday the publication in the Journal of Biological Chemistry of the detailed binding […]

August 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s

Prexton Therapeutics has launched a Phase II trial to test whether its drug foliglurax can treat the motor complications of standard levodopa therapy. The Phase II trial will enroll 165 patients across the UK, Germany, France, Austria, Spain and Italy to monitor the effects of Prexton’s foliglurax. The company is looking for patients that have been treated […]

July 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Jul 2017

Roche and Ireland’s Biggest Biopharma Take Their Parkinson’s Antibody to Phase II

Prothena and Roche are advancing their Parkinson’s antibody to Phase II, triggering a new milestone payment from what is proving a lucrative deal for Prothena. Prothena, the largest biopharma in Ireland, and its partner Roche have announced the first patient has been enrolled in a Phase II trial testing an antibody treatment for Parkinson’s. Reaching […]

July 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Araclon Biotech Alzheimers Vaccine Spain Zaragoza

News and Trends 27 Jun 2017

A Spanish Vaccine to fight Alzheimer’s Before Symptoms Appear enters Phase II

Araclon Biotech will advance to Phase II with an Alzheimer’s vaccine that could succeed where many others have failed before. Araclon Biotech, in Zaragoza, Spain, has announced today the approval from the Spanish Agency of Medicines and Medical Devices to start a Phase II trial testing its Alzheimer’s vaccine in 120 patients in 22 centers across Europe. The […]

June 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Mission Therapeutics Parkinsons research grant

News and Trends 11 Apr 2017

New Grant to Advance a Whole New Treatment Against Parkinson’s in the UK

Mission Therapeutics has received a grant to support the development of a novel approach to treating Parkinson’s that is attracting top partners worldwide. Right on time for World Parkinson’s Day today, Mission Therapeutics has announced it has been awarded a research grant from the Michael J. Fox Foundation in the US. Named after its founder, the star of […]

April 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 10 Apr 2017

“Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec

The Alzheimer’s field has been hit with a number of failures. I spoke to the COO/CBO of TauRx, whose alternative approach may yet succeed. Pharma is throwing all it can at the problem of Alzheimer’s Disease without any success to show for its efforts. Now the sixth leading cause of death across all age groups, […]

April 10, 2017 - 7 minutesmins - By Evelyn Warner

News and Trends 6 Apr 2017

Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials

Swiss Asceneuron has received regulatory approval to start its first Phase I trial of ASN120290, which is indicated for the treatment of dementia. Asceneuron was founded in 2012 as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio. Its key asset ASN120290 is an inhibitor of the O-GlcNAcase enzyme and is indicated for the treatment of diseases associated […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 10 Mar 2017

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations

Galapagos and Pharnext will work together to develop low-dose drug combinations that improve drug efficacy and target new indications. Galapagos, the biggest biotech in Belgium, has closed an R&D agreement with the French Pharnext to develop drug combinations of the billion-euro biotech’s drug candidates with already approved drugs. While Pharnext’s focus has been neurodegenerative diseases, the […]

March 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

AlzProtect crowdfunding neurodegenerative disease

News and Trends 15 Feb 2017

French Biotech bids for Crowdfunding in Neurodegenerative Disease

AlzProtect is aiming to raise €1M via equity crowdfunding to fund a Phase Ib trial in progressive supranuclear palsy (PSP). AlzProtect is a biotech in Lille, France, fighting neurodegenerative disease. To support the progression of its lead candidate, AZP2006, the company has decided to turn to an unusual source of money that seems to be […]

February 15, 2017 - 2 minutesmins - By External Contributor

News and Trends 13 Feb 2017

Biotech from the Bermuda Islands Brings Good News for Dementia Patients

Axovant Sciences has announced positive preliminary results from a Phase II trial directed at reducing hallucinations in patients with dementia. Axovant Sciences is a biotech located in Bermuda, a British tropical island in the Atlantic ocean. From there, the company develops drugs against dementia. The company was founded by young biotech entrepreneur Vivek Ramaswamy, which has […]

February 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jan 2017

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Dec 2016

Evotec closes the year partnering with Celgene to treat Alzheimer’s

Evotec is closing a fantastic financial year with another top-level partnership; Celgene has decided to trust in its iPSC platform to develop drugs for neurodegenerative diseases. Evotec is a successful drug discovery CRO based in Germany that has managed to sign partnerships with some of the biggest names in Biotech. In addition to previous deals with Bayer, Merck, […]

December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us